Onconova Therapeutics, Inc. (ONTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 375 PHEASANT RUN
NEWTOWN, PA 18940
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 38,522     
Cash and cash equivalents 38,522     
Receivables292837983559
Prepaid expense288282353189166181
Other current assets40351801406877
Other undisclosed current assets46855,08519,21423,04717,4964,586
Total current assets:39,34755,43019,78423,47417,7654,903
Noncurrent Assets
Property, plant and equipment24385250964
Other noncurrent assets11015015014912
Total noncurrent assets:254820220015876
TOTAL ASSETS:39,37255,47819,98623,67417,9234,979
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,8205,8899,7958,0665,9277,609
Employee-related liabilities   1,6501,258
Accounts payable3,8602,7574,8334,2714,0396,186
Accrued liabilities3,9603,1324,9623,795238165
Deferred revenue226226226226
Deferred revenue and credits455
Contract with customer, liability226
Other undisclosed current liabilities     2,2851,912
Total current liabilities:8,0466,11510,0218,2928,4389,976
Noncurrent Liabilities
Liabilities, other than long-term debt3,0173,2433,4693,6953,9224,091
Deferred revenue and credits4,091
Deferred revenue3,0173,2433,4693,695
Contract with customer, liability3,922
Other undisclosed noncurrent liabilities   3211131761,773
Total noncurrent liabilities:3,0173,2433,7903,8084,0985,864
Total liabilities:11,0639,35813,81112,10012,53615,840
Equity
Equity, attributable to parent28,30946,1206,17511,5745,387(11,691)
Common stock2092091,8591,11257108
Additional paid in capital491,816490,644432,858413,879387,238350,514
Accumulated other comprehensive income (loss)(33)(14)14(18)(12)3
Accumulated deficit(463,683)(444,719)(428,556)(403,399)(381,896)(362,316)
Equity, attributable to noncontrolling interest      830
Total equity:28,30946,1206,17511,5745,387(10,861)
TOTAL LIABILITIES AND EQUITY:39,37255,47819,98623,67417,9234,979

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues2262262312,1831,228787
Gross profit:2262262312,1831,228787
Operating expenses(19,853)(16,722)(25,224)(23,882)(24,510)(26,524)
Operating loss:(19,627)(16,496)(24,993)(21,699)(23,282)(25,737)
Nonoperating income1,31412481431,15130
Investment income, nonoperating 651     
Other nonoperating income66312481431,15130
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes   (208)631,5971,628
Loss from continuing operations before equity method investments, income taxes:(18,313)(16,484)(25,153)(21,493)(20,534)(24,079)
Other undisclosed income (loss) from continuing operations before income taxes(651)321    
Loss from continuing operations before income taxes:(18,964)(16,163)(25,153)(21,493)(20,534)(24,079)
Income tax expense (benefit)   (4)(10)124(13)
Loss from continuing operations:(18,964)(16,163)(25,157)(21,503)(20,410)(24,092)
Loss before gain (loss) on sale of properties:(16,163)(25,157)(21,503)(20,410)(24,092)
Net loss:(18,964)(16,163)(25,157)(21,503)(20,410)(24,092)
Net income attributable to noncontrolling interest     163 
Other undisclosed net loss attributable to parent     (326) 
Net loss available to common stockholders, diluted:(18,964)(16,163)(25,157)(21,503)(20,573)(24,092)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(18,964)(16,163)(25,157)(21,503)(20,410)(24,092)
Other comprehensive income (loss)(19)(28)32(6)(15)34
Comprehensive loss:(18,983)(16,191)(25,125)(21,509)(20,425)(24,058)
Comprehensive loss, net of tax, attributable to noncontrolling interest     (163) 
Comprehensive loss, net of tax, attributable to parent:(18,983)(16,191)(25,125)(21,509)(20,588)(24,058)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: